Elicio Therapeutics Publishes Promising Phase 1 Study Data

Elicio Therapeutics ( (ELTX) ) just unveiled an announcement.

On August 12, 2025, Elicio Therapeutics announced the publication of follow-up data from its Phase 1 AMPLIFY-201 study in Nature Medicine, highlighting significant improvements in overall survival and relapse-free survival for patients treated with ELI-002. The study demonstrated a 77% reduction in the risk of death and an 88% reduction in the risk of relapse for patients with T cell responses above the efficacy threshold, indicating the potential of ELI-002 as a transformative treatment for mKRAS-driven tumors.

The most recent analyst rating on (ELTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Elicio Therapeutics stock, see the ELTX Stock Forecast page.

Spark’s Take on ELTX Stock

According to Spark, TipRanks’ AI Analyst, ELTX is a Underperform.

Elicio Therapeutics faces significant financial challenges, with negative revenue growth and poor margins being the primary concerns. Technical analysis indicates bearish momentum, while the valuation aspect shows limited appeal. However, recent positive corporate events, such as leadership changes and clinical advancements, provide some optimism for future potential, albeit with high risk.

To see Spark’s full report on ELTX stock, click here.

More about Elicio Therapeutics

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. The company aims to leverage its Amphiphile (AMP) technology to enhance cancer-specific T cell responses, offering off-the-shelf vaccine solutions that promise low cost and rapid availability.

Average Trading Volume: 44,102

Technical Sentiment Signal: Buy

Current Market Cap: $141.3M

For detailed information about ELTX stock, go to TipRanks’ Stock Analysis page.